Niels Röckendorf

Dr. Niels Röckendorf

Research Center Borstel, Leibniz Lung Center
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Drug Delivery
Verified
Journal Article
Open access
KRKatrin Ramaker
Katrin Ramaker
MHMaik Henkel
Maik Henkel
TKThorsten Krause
Thorsten Krause
NRNiels Röckendorf
Niels Röckendorf
AFAndreas Frey
Andreas Frey
Delivering reagents into cells is a key demand in molecular medicine. The vehicle of choice is often cell penetrating peptides (CPPs), which can ferry conjugated cargo across membranes. Although numerous peptides have been shown to promote such uptake events, there has been no comprehensive comparison of individual performance under standardized conditions. We have devised a method to rapidly analyze the ability of a multitude of CPP conjugates to carry a model cargo into HeLa cells. Sequence information for 474 CPPs was collected from literature sources, and the respective peptides were synthesized and modified with carboxyfluorescein (FAM) as model cargo. All candidates were evaluated in an identical uptake test, and transport was quantified using cellular fluorescence intensities. Substantial differences in the ability to carry the fluorophore into the cells were observed, with transport performance differing by a factor of 70 between the best CPP investigated and cargo alone. Strong correlations were observed between uptake efficiency and both sequence length and the presence of positive net charge. A compilation of the 20 top performers with regard to cargo delivery performance and cell compatibility is provided.

14 September 2020 in IEEE Access
Verified
Journal Article
Open access
PZPouya Soltani Zarrin
Pouya Soltani Zarrin
NRNiels Röckendorf
Niels Röckendorf
CWChristian Wenger
Christian Wenger
Chronic Obstructive Pulmonary Disease (COPD) is a life-threatening lung disease and a major cause of morbidity and mortality worldwide. Although a curative therapy has yet to be found, permanent monitoring of biomarkers that reflect the disease progression plays a pivotal role for the effective management of COPD. The accurate examination of respiratory tract fluids like saliva is a promising approach for staging disease and predicting its upcoming exacerbations in a Point-of-Care (PoC) environment. However, the concurrent consideration of patients' demographic and medical parameters is necessary for achieving accurate outcomes. Therefore, Machine Learning (ML) tools can play an important role for analyzing patient data and providing comprehensive results for the recognition of COPD in a PoC setting. As a result, the objective of this research work was to implement ML tools on data acquired from characterizing saliva samples of COPD patients and healthy controls as well as their demographic information for PoC recognition of the disease. For this purpose, a permittivity biosensor was used to characterize dielectric properties of saliva samples and, subsequently, ML tools were applied on the acquired data for classification. The XGBoost gradient boosting algorithm provided a high classification accuracy and sensitivity of 91.25% and 100%, respectively, making it a promising model for COPD evaluation. Integration of this model on a neuromorphic chip, in the future, will enable the real-time assessment of COPD in PoC, with low cost, low energy consumption, and high patient privacy. In addition, constant monitoring of COPD in a near-patient setup will enable the better management of the disease exacerbations.

29 October 2015 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
AHArne Homann
Arne Homann
NRNiels Röckendorf
Niels Röckendorf
AKArno Kromminga
Arno Kromminga
AFAndreas Frey
Andreas Frey
UJUta Jappe
Uta Jappe
Autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease are treated with TNF-alpha-blocking antibodies such as infliximab and adalimumab. A common side effect of therapeutic antibodies is the induction of anti-drug antibodies, which may reduce therapeutic efficacy. In order to reveal immunogenic epitopes on infliximab which are responsible for the adverse effects, sera from patients treated with infliximab were screened by ELISA for anti-infliximab antibodies. Sera containing high levels of anti-drug-antibodies (>1.25 µg/ml) were analyzed in an oligopeptide microarray system containing immobilized 15-meric oligopeptides from the infliximab amino acid sequence. Immunogenic infliximab IgG-epitopes were identified by infrared fluorescence scanning and comparison of infliximab-treated patients versus untreated controls. Six relevant epitopes on infliximab were recognized by the majority of all patient sera: 4 in the variable and 2 in the constant region. Three of the epitopes in the variable region are located in the TNF-alpha binding region of infliximab. The fourth epitope of the variable part of infliximab is located close to the TNF-alpha binding region and contains an N-glycosylation sequon. The sera positive for anti-infliximab antibodies do not contain antibodies against adalimumab as determined by ELISA. Thus, there is no infliximab–adalimumab cross-reactivity as determined by these systems. Our data shall contribute to a knowledge-based recommendation for a potentially necessary therapy switch from infliximab to another type of TNF-alpha-blocker. The characterization of immunogenic epitopes on therapeutic monoclonal antibodies using unprocessed patient sera shall lead to direct translational aspects for the development of less immunogenic therapeutic antibodies. Patients benefit from less adverse events and longer lasting drug effects.

16 January 2019 in Healthcare
Verified
Journal Article
Open access
PDF file
PZPouya Soltani Zarrin
Pouya Soltani Zarrin
FJFarabi Ibne Jamal
Farabi Ibne Jamal
NRNiels Röckendorf
Niels Röckendorf
CWChristian Wenger
Christian Wenger
Chronic Obstructive Pulmonary Disease (COPD) is a life-threatening lung disease affecting millions of people worldwide. Although the majority of patients with objective COPD go undiagnosed until the late stages of their disease, recent studies suggest that the regular screening of sputum viscosity could provide important information on the disease detection. Since the viscosity of sputum is mainly defined by its mucin–protein and water contents, dielectric biosensors can be used for detection of viscosity variations by screening changes in sputum’s contents. Therefore, the objective of this work was to develop a portable dielectric biosensor for rapid detection of viscosity changes and to evaluate its clinical performance in characterizing viscosity differences of saliva samples collected from COPD patients and Healthy Control (HC). For this purpose, a portable dielectric biosensor, capable of providing real-time measurements, was developed. The sensor performance for dielectric characterization of mediums with high water content, such as saliva, was evaluated using isopropanol–water mixtures. Subsequently, saliva samples, collected from COPD patients and HC, were investigated for clinical assessments. The radio frequency biosensor provided high repeatability of 1.1% throughout experiments. High repeatability, ease of cleaning, low-cost, and portability of the biosensor made it a suitable technology for point-of-care applications.

2 February 2022 in Membranes
Verified
Journal Article
Open access
PDF file
NRNiels Röckendorf
Niels Röckendorf
CNChristian Nehls
Christian Nehls
TGThomas Gutsmann
Thomas Gutsmann
A multitude of membrane active peptides exists that divides into subclasses, such as cell penetrating peptides (CPPs) capable to enter eukaryotic cells or antimicrobial peptides (AMPs) able to interact with prokaryotic cell envelops. Peptide membrane interactions arise from unique sequence motifs of the peptides that account for particular physicochemical properties. Membrane active peptides are mainly cationic, often primary or secondary amphipathic, and they interact with membranes depending on the composition of the bilayer lipids. Sequences of these peptides consist of short 5–30 amino acid sections derived from natural proteins or synthetic sources. Membrane active peptides can be designed using computational methods or can be identified in screenings of combinatorial libraries. This review focuses on strategies that were successfully applied to the design and optimization of membrane active peptides with respect to the fact that diverse features of successful peptide candidates are prerequisites for biomedical application. Not only membrane activity but also degradation stability in biological environments, propensity to induce resistances, and advantageous toxicological properties are crucial parameters that have to be considered in attempts to design useful membrane active peptides. Reliable assay systems to access the different biological characteristics of numerous membrane active peptides are essential tools for multi-objective peptide optimization.

22 May 2006
Verified
Book Chapter
Closed access
PDF file
JHJürgen Helfmann
Jürgen Helfmann
UBUwe Bindig
Uwe Bindig
BMBarbara Meckelein
Barbara Meckelein
KWKatrin Wehry
Katrin Wehry
NRNiels Röckendorf
Niels Röckendorf
AFAndreas Frey
Andreas Frey